PRINCETON, N.J. (Map) - PRINCETON, N.J., May 16 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) is scheduled to host a webcast review and discussion of the ipilimumab data presented during the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The live webcast will begin at 7:00 a.m. CDT on Monday, June 2, 2008. The webcast can be accessed on Medarex's website at www.medarex.com and will be archived and available for replay for at least 14 days.

Additional or updated data beyond the information submitted in the abstracts may be included in the following presentations at ASCO:

    Ipilimumab Presentations in Melanoma
    -- "Antitumor response and new lesions in advanced melanoma patients on
       ipilimumab treatment" (Abstract #3020, Developmental Therapeutics:
       Immunotherapy Session) - Poster presentation and discussion from
       2:00 p.m. to 6:00 p.m. local time on Friday, May 30, 2008.
    -- "Long-term survival of patients with advanced melanoma who received
       ipilimumab administered at 10mg/kg every 3 weeks for 4 doses (induction
       dosing)" (Abstract #3018, Developmental Therapeutics: Immunotherapy
       Session) - Poster presentation and discussion from 2:00 p.m. to
       6:00 p.m. local time on Friday, May 30, 2008.
    -- "Potential immune biomarkers of gastrointestinal toxicities and
       efficacy in patients with advanced melanoma treated with ipilimumab
       with or without prophylactic budesonide" (Abstract #3022, Developmental
       Therapeutics: Immunotherapy Session) - Poster presentation and
       discussion from 2:00 p.m. to 6:00 p.m. local time on Friday, May 30,
       2008.
    -- "Novel efficacy criteria for antitumor activity to immunotherapy using
       the example of ipilimumab, an anti-CTLA-4 monoclonal antibody"
       (Abstract #3008, Developmental Therapeutics: Immunotherapy Session) -
       Oral presentation beginning at 4:30 p.m. local time one Saturday, May
       31, 2008.
    -- "Effect of prior treatment status on the efficacy and safety of
       ipilimumab monotherapy in treatment-naive and previously treated
       patients with advanced melanoma" (Abstract #9055, Melanoma Session) -
       Poster presentation from 2:00 p.m. to 6:00 p.m. local time on Saturday,
       May 31, 2008.
    -- "An analysis of the effectiveness of specific guidelines for the
       management of ipilimumab-mediated diarrhea/colitis: prevention of
       gastrointestinal perforation and/or colectomy" (Abstract #9063,
       Melanoma Session) - Poster presentation from 2:00 p.m. to 6:00 p.m.
       local time on Saturday, May 31, 2008.
    -- "Model-based evaluation of ipilimumab dosage regimen in patients with
       advanced melanoma" (Abstract #9073, Melanoma Session) - Poster
       presentation from 2:00 p.m. to 6:00 p.m. local time on Saturday, May
       31, 2008.
    -- "Safety and efficacy of ipilimumab with or without prophylactic
       budesonide in treatment-naive and previously treated patients with
       advanced melanoma" (Abstract #9010, Melanoma Session) - Oral
       presentation beginning at 10:15 a.m. local time on Sunday, June 1,
       2008.
    -- "Efficacy and safety of ipilimumab induction and maintenance dosing in
       patients with advanced melanoma who progressed on one or more prior
       therapies" (Abstract #9021, Melanoma Session) - Poster presentation and
       discussion from 2:00 p.m. to 6:00 p.m. local time on Sunday, June 1,
       2008.
    -- "Disease control and long-term survival in chemotherapy-naive patients
       with advanced melanoma treated with ipilimumab (MDX-010) with or
       without dacarbazine" (Abstract #9022, Melanoma Session) - Poster
       presentation and discussion from 2:00 p.m. to 6:00 p.m. local time on
       Sunday, June 1, 2008.
    -- "Dose effect of ipilimumab in patients with advanced melanoma: results
       from a phase 2, randomized, dose-ranging study" (Abstract #9025,
       Melanoma Session) - Poster presentation and discussion from 2:00 p.m.
       to 6:00 p.m. local time on Sunday, June 1, 2008.
    -- "Prolonged survival in objective responders to ipilimumab therapy"
       (Abstract #20004) - Publication only.
    Ipilimumab Presentations in Prostate Cancer
    -- "Phase 1 trial of ipilimumab (IPI) alone and in combination with
       radiotherapy (XRT) in patients with metastatic castration resistant
       prostate cancer (mCRPC)" (Abstract #5004, New Targeted Strategies for
       Patients with Prostate Cancer Session) - Oral presentation beginning at
       11:30 a.m. local time on Monday, June 2, 2008.
    -- "Expanded phase 1 combination trial of GVAX immunotherapy for prostate
       cancer and ipilimumab in patients with metastatic hormone-refractory
       prostate cancer (mHRPC)" (Abstract #5146, Genitourinary Cancer Session)
       - Poster presentation from 8:00 a.m. to 12:00 p.m. local time on
       Saturday, May 31, 2008.
    Additional Presentations at ASCO
    -- "Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal
       antibody, in patients with selected refractory or relapse malignancies"
       (Abstract #3006, Developmental Therapeutics: Immunotherapy Session) -
       Oral presentation beginning at 4:00 p.m. local time on Saturday, May
       31, 2008.
    -- "Antitumor activity of anti-CTLA-4 monoclonal antibody (mAb) in
       combination with ixabepilone in preclinical tumor models" (Abstract
       #3048, Developmental Therapeutics: Immunotherapy Session) - Poster
       presentation from 2:00 p.m. to 6:00 p.m. local time on Sunday, June 1,
       2008.
    -- "Effect of a fully human anti-CD70 antibody on apoptosis and
       dephosphorylation of MAPK proteins in chronic lymphocytic leukemia"
       (Abstract #3073, Developmental Therapeutics: Immunotherapy Session) -
       Poster presentation from 2:00 p.m. to 6:00 p.m. local time on Sunday,
       June 1, 2008.

More information about the ASCO Annual Meeting may be found at www.asco.org.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, the statements relating to Medarex's advances related to its products in this press release may constitute forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of antibody products in patients, uncertainties related to product manufacturing, the need for additional capital, compliance with regulatory requirements, risks associated with the use of hazardous substances and risks associated with the enforceability of our patents as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. There can be no assurance that such development efforts will succeed or that developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.